新手上路
初級會員
- 舊站積分
- 0
- 舊站發表文章數
- 0
|
樓主 |
發表於 2022-9-7 16:09:14
|
顯示全部樓層
Novavax 主流媒體不會報 & 疫苗梗圖
https://mainichi.jp/english/articles/20220906/p2a/00m/0na/009000c
[B]Man dies after receiving Novavax COVID shot in Japan[/B][/SIZE]
September 6, 2022 (Mainichi Japan)
TOKYO -- A 29-year-old man died a day after receiving U.S. pharmaceutical firm Novavax Inc.'s COVID-19 vaccine shot in Japan, but a causal relation remains unclear.
The Ministry of Health, Labor and Welfare on Sept. 2 reported the death of the man in an expert panel meeting to evaluate the safety of vaccines. Though the ministry received a report from the medical institution, saying, "It was a sudden death, and a link with vaccination such as the possibility of heart muscle inflammation cannot be denied," a causal relation apparently could not be confirmed due to a lack of objective information. This was the first reported death in Japan after receiving Novavax's vaccine.
According to the health ministry, the man received a second inoculation on Aug. 17. He developed a fever from the next morning and was recuperating at home. The man suffered cardiopulmonary arrest in the evening and was rushed to the hospital, but he was confirmed dead.
Novavax's serum is the fourth COVID-19 vaccine that the Japanese government has approved, and is manufactured domestically by Takeda Pharmaceutical Co., which has been provided with the technology. It is called a recombinant protein vaccine, and has been used for booster shots as well as first and second shots.
(Japanese original by Hidenori Yazawa, Lifestyle and Medical News Department)
[B]A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax ®) COVID-19 Vaccination[/B][/SIZE]
https://pubmed.ncbi.nlm.nih.gov/36038960/
Abstract
Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea. |
|